Shares of the leading health and wellness platform Hims & Hers (HIMS) are under pressure following the company’s fourth-quarter earnings release. Despite delivering strong financial results, investor sentiment has been dampened by concerns over near-term profit margins and the loss of potential revenue from compounded semaglutide.
Hims & Hers reported robust revenues of $481 million for Q4 and $1.5 billion for 2024, marking year-over-year growth rates of 95% and 69%, respectively. This growth reflects its ability to attract and retain subscribers along with scaling newer offerings such as weight-loss treatments.
